http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#Head http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#provenance http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#pubinfo http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion http://purl.obolibrary.org/obo/DOID_3393 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_3393 http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00953 http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association http://www.w3.org/2000/01/rdf-schema#label "Rizatriptan benzoate tablets are contraindicated in patients with: * Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings and Precautions ( 5.1 * Coronary artery vasospasm including Prinzmetal's angina [see Warnings and Precautions ( 5.1 * History of stroke or transient ischemic attack (TIA) [see Warnings and Precautions ( 5.4 * Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 * Ischemic bowel disease [see Warnings and Precautions ( 5.5 * Uncontrolled hypertension [see Warnings and Precautions ( 5.8 * Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.2 7.3 * Hemiplegic or basilar migraine. * Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions ( 7.5 12.3 * Hypersensitivity to rizatriptan benzoate tablets or rizatriptan benzoate orally disintegrating tablets (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 * History of ischemic heart disease or coronary artery vasospasm ( 4 * History of stroke or transient ischemic attack ( 4 * Peripheral vascular disease ( 4 * Ischemic bowel disease ( 4 * Uncontrolled hypertension ( 4 * Recent (within 24 hours) use of another 5-HT 1 4 * Hemiplegic or basilar migraine ( 4 * MAO-A inhibitor used in the past 2 weeks ( 4 * Hypersensitivity to rizatriptan benzoate( 4" http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#association https://w3id.org/biolink/vocab/relation https://schema.org/MedicalContraindication https://identifiers.org/drugbank:DB00953 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#provenance http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#pubinfo http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#sig http://purl.org/nanopub/x/hasSignature hpr6RALm/XiZ728FefzqvgvfH47zAddRv2y/RB5akx6Io8Bs21nKstq9xcPjflUbDg8KkCdRtsDSbM8ry733FIjrCUtQN5nsY9N5i0B/1HW4PgRADCyPdyvD97FIMhoSFuhCkwvt+1dZ/fUDPGvIAQSh0AbocjYd2iMXgoIksvA= http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://purl.org/dc/terms/created 2021-08-23T18:05:19.392+02:00 http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAal1_aAtyYL58uVgxyJR_lUFgwv7OA-Gau0lW0l9cHIU https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY